* Idec Pharmaceuticals Corp. of San Diego...
- Share via
* Idec Pharmaceuticals Corp. of San Diego said third-quarter profit rose 43% to $38.4 million, or 22 cents a share. Revenue increased 49% to $103.7 million, boosted by sales of Rituxan, which Idec developed with Genentech.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
